Calum Heslop

Dr. Calum Heslop

Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SCSamantha Cooper
Samantha Cooper
EBEleanor Boyle
Eleanor Boyle
SJSophie Jefferson
Sophie Jefferson
CHCalum Heslop
Calum Heslop
PMPirathini Mohan
Pirathini Mohan
Jeanette WoolardJeanette Woolard
Jeanette Woolard
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the virus responsible for the COVID-19 pandemic. Patients may present as asymptomatic or demonstrate mild to severe and life-threatening symptoms. Although COVID-19 has a respiratory focus, there are major cardiovascular complications (CVCs) associated with infection. The reported CVCs include myocarditis, heart failure, arrhythmias, thromboembolism and blood pressure abnormalities. These occur, in part, because of dysregulation of the Renin–Angiotensin–Aldosterone System (RAAS) and Kinin–Kallikrein System (KKS). A major route by which SARS-CoV-2 gains cellular entry is via the docking of the viral spike (S) protein to the membrane-bound angiotensin converting enzyme 2 (ACE2). The roles of ACE2 within the cardiovascular and immune systems are vital to ensure homeostasis. The key routes for the development of CVCs and the recently described long COVID have been hypothesised as the direct consequences of the viral S protein/ACE2 axis, downregulation of ACE2 and the resulting damage inflicted by the immune response. Here, we review the impact of COVID-19 on the cardiovascular system, the mechanisms by which dysregulation of the RAAS and KKS can occur following virus infection and the future implications for pharmacological therapies.

22 October 2021 in Medical Teacher
Verified
Journal Article
Closed access
IWIsobel Walker
Isobel Walker
EBEleanor Kate Brierley
Eleanor Kate Brierley
TPTalia Patel
Talia Patel
RJRaisa Jaffer
Raisa Jaffer
MRMilap Rajpara
Milap Rajpara
RPRakesh Patel
Rakesh Patel
Leading sportspeople across 2021, such as Simone Biles (US gymnast), Naomi Osaka (Japanese tennis player) and Ben Stokes (English cricketer), have talked openly about the pressure of performing on the highest stage, including the challenge of managing mental health when engaged in elite competition. The withdrawal of Simone Biles midway through the women’s team competition at the Tokyo 2020 Olympic Games propelled what was seemingly a debate within sport, into what is increasing becomingly wider societal conversation around mental health. The stories of sportspeople struggling to perform at the highest level with mental health contributing to their difficulties, has inevitably prompted much reflection within medical education among teachers and students alike, about parallels in our domain around assessment, feedback and support. The stories demonstrate that mental health problems affect everyone, including those who are at their peak physically, and those who are among the finest on the planet in terms of physical and sporting ability. The same is true within medical education of our students, who are also our future doctors. However, curriculum conversations about assessment, feedback and student support may not be as student-centred as they could be, or perhaps as they should be, with mental health possibly still being a taboo-subject or something associated with stigma within medical education. Here is another opportunity for medical education to learn from other disciplines, such as sports psychology, and now is the time for taking and applying those lessons: not just those around improving technical performance, but those around properly caring, being compassionate, and looking after our future Olympian equivalents.

17 June 2026 in World Journal of Urology
Verified
Journal Article
Closed access
DMDaniel Peter McNicholas
Daniel Peter McNicholas
CHCalum Heslop
Calum Heslop
KAKetan Agarwal
Ketan Agarwal
EDEloise Dexter
Eloise Dexter
RWRobin Weston
Robin Weston
VHVishwanath Hanchanale
Vishwanath Hanchanale

30 August 2026 in Clinical Medicine
Verified
Journal Article
Open access
TPTalia Patel
Talia Patel
CHCalum Heslop
Calum Heslop
MRMilap Rajpara
Milap Rajpara
SKShivaali Karelia
Shivaali Karelia
RPRakesh Patel
Rakesh Patel

23 June 2026 in Journal of Surgical Education
Verified
Journal Article
Closed access
CHCalum Heslop
Calum Heslop
TPTalia Patel
Talia Patel
RJRobert Jay
Robert Jay
RPRakesh Patel
Rakesh Patel
JSJohn Sandars
John Sandars

14 September 2024 in European Respiratory Journal
Verified
Conference Paper
Closed access
CHCalum Heslop
Calum Heslop
RBRachel Burton
Rachel Burton
FFFred Fyles
Fred Fyles
RNRebecca Nightingale
Rebecca Nightingale
AWAilis Walsh
Ailis Walsh
HBHassan Burhan
Hassan Burhan
Background: Large airways collapse (LAC) is defined as ≥50% reduction in large airway diameter visualised either on dynamic CT or during bronchoscopy. Case series have suggested a benefit of continuous positive airway pressure (CPAP) in patients with LAC. We aim to describe the diagnosis, management and exacerbation burden in our LAC population. Methods: Patients with confirmed LAC were included. Demographic and clinical characteristics, including mode of diagnosis, treatment and number of exacerbations with antibiotics with or without steroids in the last 12 months (Jan 2023 to Jan 2024) were collected. Continuous data was summarised with medians and interquartile range (IQR). Results: 71 patients [female 83%, median age 59 years (IQR 50,68)] with LAC [evidenced by CT in 83% (n=59), bronchoscopy in 10% (n=7), both in 7% (n=5)] were identified. 48% were on specific treatment for LAC (13 hypertonic saline, 16 CPAP, 5 hypertonic saline and CPAP). Overall median annualised exacerbation risk (AER) was 2 (IQR 0,4). AER for those on no treatment was 2 (IQR 0,4). AER for those on hypertonic saline alone was 4 (IQR 1,5). AER for those on CPAP and hypertonic saline was 3 (IQR 0,4). AER for those on CPAP alone was 0.5 (IQR 0,3). AER for those on CPAP with or without hypertonic saline was 1 (IQR 0,4). Conclusion: Patients treated with hypertonic saline alone did not have a reduction in AER. Those treated with CPAP did. CPAP treatment for LAC warrants further investigation.